Share on StockTwits

Tornier NV (NASDAQ:TRNX) has been given an average recommendation of “Buy” by the eight ratings firms that are currently covering the company, American Banking reports. Three research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $21.00.

Tornier NV (NASDAQ:TRNX) traded up 12.57% on Friday, hitting $21.94. 126,674 shares of the company’s stock traded hands. Tornier NV has a 52-week low of $15.17 and a 52-week high of $24.35. The stock’s 50-day moving average is $22.29 and its 200-day moving average is $20.51. The company’s market cap is $1.065 billion.

Tornier NV (NASDAQ:TRNX) last announced its earnings results on Thursday, August 7th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by $0.04. The company had revenue of $86.85 million for the quarter, compared to the consensus estimate of $79.40 million. During the same quarter in the previous year, the company posted ($0.28) earnings per share. The company’s revenue for the quarter was up 11.2% on a year-over-year basis. On average, analysts predict that Tornier NV will post $-0.45 earnings per share for the current fiscal year.

A number of analysts have recently weighed in on TRNX shares. Analysts at BMO Capital Markets upgraded shares of Tornier NV from a “market perform” rating to an “outperform” rating in a research note on Friday. They now have a $24.00 price target on the stock, up previously from $20.00. Separately, analysts at TheStreet upgraded shares of Tornier NV from a “sell” rating to a “hold” rating in a research note on Friday, June 6th. Finally, analysts at Barclays raised their price target on shares of Tornier NV from $23.00 to $26.00 in a research note on Thursday, June 5th. They now have an “overweight” rating on the stock.

Tornier N.V. (NASDAQ:TRNX) is a global medical device company focused on surgeons that treat musculoskeletal injuries and disorders of the shoulder, elbow, wrist, hand, ankle and foot.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.